Literature DB >> 14652781

Multicentre study of the molecular epidemiology, serotypes and antimicrobial susceptibility patterns of invasive Streptococcus pneumoniae invasive isolated from children in the Ille de France area.

J-W Decousser1, P Ovetchkine, A Collignon, C Chaplain, E Estrangin, A Fremaux, P Reinert, P Foucaud, J-C Ghnassia, R Cohen, J Gaudelus, P-Y Allouch.   

Abstract

Between January 1997 and April 2002, 73 consecutive invasive strains of Streptococcus pneumoniae were isolated from children under 16 years of age in four hospitals in suburban Paris. Their genetic diversity was investigated by serotyping and analysis of pulsed-field gel electrophoresis restriction patterns. Antibiotic susceptibility patterns were analysed by disk susceptibility testing and determination of minimal inhibitory concentrations. The genetic basis of macrolide resistance was investigated by polymerase chain reaction. Studies of penicillin and vancomycin tolerance were performed for each strain. Despite the high prevalence (45.2%) of penicillin-nonsusceptible Streptococcus pneumoniae, resistance to amoxicillin (1.4%) was rare, and no strain was resistant to cefotaxime. Overall, 4.1% of pneumococcal strains were resistant to penicillin. Penicillin or vancomycin tolerance was not detected in any of the 73 strains studied. Of the erythromycin-resistant strains (48%), all but one carried the ermB gene. No strains showing a decreased susceptibility to ciprofloxacin (MIC, >4 mg/l) or overexpressing an efflux pump inhibited by reserpine were isolated. The serotypes found, in order of frequency, were as follows: 18C, 14, 6B, 19F, 19A, 9V, 23F, 1, 7F, 9A, 38. Strains of penicillin-nonsusceptible Streptococcus pneumoniae belonged predominantly to serotypes 14, 6B, 9V, 9A, 23F, 19F and 19A. The seven-valent conjugated vaccine covered 85.5% of the serogroups isolated in children under 2 years of age and 65.6% of the serogroups identified in children over 2 years of age. The genetic analysis showed a high identity for some serotypes, such as 14/9V, 6B and 23F. The use of the seven-valent conjugated vaccine is a critical measure to prevent invasive pneumococci infections in children in the Ille de France area.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14652781     DOI: 10.1007/s10096-003-1032-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  46 in total

1.  Molecular evolution in a multidrug-resistant lineage of Streptococcus pneumoniae: emergence of strains belonging to the serotype 6B Icelandic clone that lost antibiotic resistance traits.

Authors:  S E Vilhelmsson; A Tomasz; K G Kristinsson
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

Review 2.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

3.  Typing of pneumococci by using 12 pooled antisera.

Authors:  U B Sørensen
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

4.  An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations.

Authors:  Carrie L Byington; LaShonda Y Spencer; Timothy A Johnson; Andrew T Pavia; Daniel Allen; Edward O Mason; Sheldon Kaplan; Karen C Carroll; Judy A Daly; John C Christenson; Matthew H Samore
Journal:  Clin Infect Dis       Date:  2002-01-03       Impact factor: 9.079

5.  Macrolide resistance phenotypes and genotypes in French clinical isolates of Streptococcus pneumoniae. Observatoire de Normandie du Pneumocoque.

Authors:  P Angot; M Vergnaud; M Auzou; R Leclercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-10       Impact factor: 3.267

6.  Clinical isolates of Streptococcus pneumoniae that exhibit tolerance of vancomycin.

Authors:  B Henriques Normark; R Novak; A Ortqvist ; G Källenius; E Tuomanen; S Normark
Journal:  Clin Infect Dis       Date:  2001-02-09       Impact factor: 9.079

7.  Emergence of vancomycin tolerance in Streptococcus pneumoniae.

Authors:  R Novak; B Henriques; E Charpentier; S Normark; E Tuomanen
Journal:  Nature       Date:  1999-06-10       Impact factor: 49.962

8.  Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.

Authors:  D J Bast; D E Low; C L Duncan; L Kilburn; L A Mandell; R J Davidson; J C de Azavedo
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

9.  Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates from Bulgaria.

Authors:  L Setchanova; A Tomasz
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

10.  Phenotypic and genetic diversity of invasive pneumococcal isolates recovered from French children.

Authors:  Catherine Doit; Chawki Loukil; Pierre Geslin; Edouard Bingen
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

View more
  3 in total

1.  Invasive Streptococcus pneumoniae in France: antimicrobial resistance, serotype, and molecular epidemiology findings from a monthly national study in 2000 to 2002.

Authors:  Jean-Winoc Decousser; Patrick Pina; Florent Viguier; Franc Picot; Patrice Courvalin; Pierre Allouch
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

2.  Burden of paediatric invasive pneumococcal disease in Europe, 2005.

Authors:  E D G McIntosh; B Fritzell; M A Fletcher
Journal:  Epidemiol Infect       Date:  2006-09-07       Impact factor: 2.451

3.  Antibiotic innovation may contribute to slowing the dissemination of multiresistant Streptococcus pneumoniae: the example of ketolides.

Authors:  Lulla Opatowski; Laura Temime; Emmanuelle Varon; Roland Leclercq; Roland Leclerc; Henri Drugeon; Pierre-Yves Boëlle; Didier Guillemot
Journal:  PLoS One       Date:  2008-05-07       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.